nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

24.10.2018 | Original Article

Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

verfasst von: Yu Bai, Hai-wei Wu, Yan-hua Zhang

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.

Methods

The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.

Results

In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each CYP2D6*10 genotype group (p < 0.05). The CC genotype was associated with higher concentrations of 4-OH-TAM than the CT/TT genotype (p < 0.05). However, there were no statistically significant between-group differences in serum concentrations of TAM (p > 0.05). Publication bias and sensitivity analyses confirmed that the meta-analysis results were stable and reliable.

Conclusions

CYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.

Nur mit Berechtigung zugänglich

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Shah R, O’Regan RM (2018) Adjuvant endocrine therapy. Cancer Treat Res 173:15–29CrossRefPubMed

Early Breast Cancer Trialists’Collaborative Group (EBCTCG) (2005) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patients-level meta-analysis of randomized trials. Lancet 378(9793):771–784CrossRef

Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (2013) PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genom 23:643–647. https://doi.org/10.1097/FPC.0b013e3283656bc1 CrossRef

Woo HI, Lee SK, Kim J, Kim SW, Yu J, Bae SY, Lee JE, Nam SJ, Lee SY (2017) Variations in serum concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget 8:100296–100311. https://doi.org/10.18632/oncotarget.22220 CrossRefPubMedPubMedCentral

Thota K, Prasad K, Basaveswara Rao MV (2018) Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy. Asian Pac J Cancer Prev 19:343–350. https://doi.org/10.22034/APJCP.2018.19.2.343 CrossRefPubMedPubMedCentral

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD (2015) Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet 54:797–810. https://doi.org/10.1007/s40262-015-0273-3 CrossRefPubMedPubMedCentral

Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478. https://doi.org/10.1007/s00280-004-0926-7 CrossRefPubMed

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159. https://doi.org/10.1023/B:BREA.0000025406.31193.e8 CrossRefPubMed

10.

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718–725CrossRefPubMed

11.

Saladores P, Murdter T, Eccles D, Chowbay B, Zqheib NK, Winter S, Ganchew B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Nq RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenom J 15(1):84–94CrossRef

12.

Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, Chowbay B, Khor CC, Tfayli A, Zgheib NK, Eichelbaum M, Schwab M, Brauch H (2017) Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol 8:582. https://doi.org/10.3389/fphar.2017.00582 CrossRefPubMedPubMedCentral

13.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther 103:770–777. https://doi.org/10.1002/cpt.1007 CrossRefPubMed

14.

Chin FW, Chan SC, Abdul Rahman S, Noor Akmal S, Rosli R (2016) CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of malaysian breast cancer patients. Breast J 22:54–62. https://doi.org/10.1111/tbj.12518 CrossRefPubMed

15.

Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C (2012) CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenom Pers Med 5:149–153. https://doi.org/10.2147/PGPM.S32160 CrossRef

16.

Yin SJ, Ni YB, Wang SM, Wang X, Lou YQ, Zhang GL (2012) Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther 37:364–369. https://doi.org/10.1111/j.1365-2710.2011.01298.x CrossRefPubMed

17.

Lan B, Ma F, Zhai X, Li Q, Chen S, Wang J, Fan Y, Luo Y, Cai R, Yuan P, Zhang P, Li Q, Xu B (2018) The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer. https://doi.org/10.1002/ijc.31291 CrossRefPubMedPubMedCentral

18.

Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N (2013) Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients. Breast Cancer (Dove Med Press) 5:73–78. https://doi.org/10.2147/BCTT.S47172 CrossRef

19.

Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137. https://doi.org/10.1002/gepi.20048 CrossRefPubMed

20.

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13 CrossRefPubMedPubMedCentral

21.

Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457. https://doi.org/10.1002/sim.2380 CrossRefPubMed

22.

Tian C, Yang Y, Li H (2014) Clinical analysis of CYP2D6 gene polymorphism with serum concentration of tamoxifen and 4-hydroxytamoxifen. Sichuan Med J 35(1):4–6

23.

Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y (2008) Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423–1429. https://doi.org/10.1093/annonc/mdn155 CrossRefPubMed

24.

Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V (2017) Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast Cancer (Dove Med Press) 9:249–256. https://doi.org/10.2147/BCTT.S125745 CrossRef

25.

Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837–3845. https://doi.org/10.1200/JCO.2007.11.4850 CrossRefPubMed

26.

Zhang YX, Li YF, Chen B, Zhang WX, Cai WM (2010) Correlation between polymorphisms of CYP3A5 and CYP2D6 genotypes with concentration of tamoxifen and its activity metabolism 4-hydroxytamoxifen in Chinese breast cancer patients. China Pharmacist 13(9):1229–1232

27.

Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, Wong M, Lee EJ, Chowbay B (2011) Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71:737–750. https://doi.org/10.1111/j.1365-2125.2011.03905.x CrossRefPubMedPubMedCentral

28.

Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 131:137–145. https://doi.org/10.1007/s10549-011-1777-7 CrossRefPubMed

29.

Yang X, Luo B, Wu B (2013) Association between CYP2D6 polymorphism and serum concentration of endoxifen in breast cancer patients. Chin J Cancer Prev Treat 20(12):922–925

30.

Lei L, Wang X, Wu XD, Wang Z, Chen ZH, Zheng YB, Wang XJ (2016) Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res 8:3585–3592PubMedPubMedCentral

31.

Johnson JA, Weitzel KW (2016) Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin Pharmacol Ther 99:154–156. https://doi.org/10.1002/cpt.273 CrossRefPubMed

32.

Lu J, Li H, Guo P, Shen R, Luo Y, Ge Q, Shi W, Li Y, Zhu W (2017) The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther 10:5429–5437. https://doi.org/10.2147/OTT.S149197 CrossRefPubMedPubMedCentral

33.

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C (2013) Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen therapy. Pharmgenom Pers Med 6:37–47

34.

Kiyotani K, Mushiroda T, Sasa M (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99(5):995–999CrossRefPubMed

35.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017) Serum concentration of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res 19(1):125CrossRefPubMedPubMedCentral

36.

Chau SB, Thomas RE (2015) The AmpliChip: a review of its analytic and clinical validity and clinical utility. Curr Drug Saf 10:113–124CrossRefPubMed

37.

de Leon J, Susce MT, Murray-Carmichael E (2006) The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 10:135–151CrossRefPubMed

38.

Neven P, Jongen L, Lintermans A, Van AK, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudomne AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van HS, Lybaert W, Van GJ, Paridaens R, Vergote I, Dezentje VO, Van CB, Guchelaar HJ (2018) Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res 24(10):2312–2318CrossRefPubMed

Titel: Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis
verfasst von: Yu Bai
Hai-wei Wu
Yan-hua Zhang
Publikationsdatum: 24.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3703-8

Springer Medizin

Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Autophagy and its potent modulators from phytochemicals in cancer treatment

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms

Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy

Awakening the “guardian of genome”: reactivation of mutant p53

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie